AbbVie Inc. (NYSE:ABBV) Shares Sold by JLB & Associates Inc.

JLB & Associates Inc. decreased its position in AbbVie Inc. (NYSE:ABBV) by 2.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 44,268 shares of the company’s stock after selling 1,020 shares during the quarter. JLB & Associates Inc.’s holdings in AbbVie were worth $7,866,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ABBV. Forte Capital LLC ADV raised its position in shares of AbbVie by 0.7% in the fourth quarter. Forte Capital LLC ADV now owns 16,356 shares of the company’s stock valued at $2,906,000 after buying an additional 111 shares during the last quarter. ING Groep NV boosted its position in AbbVie by 78.7% during the fourth quarter. ING Groep NV now owns 598,335 shares of the company’s stock worth $106,324,000 after acquiring an additional 263,557 shares during the last quarter. O Brien Greene & Co. Inc grew its stake in AbbVie by 0.9% in the 4th quarter. O Brien Greene & Co. Inc now owns 10,964 shares of the company’s stock worth $1,948,000 after acquiring an additional 99 shares during the period. Zullo Investment Group Inc. raised its holdings in AbbVie by 1.8% in the 4th quarter. Zullo Investment Group Inc. now owns 5,214 shares of the company’s stock valued at $927,000 after acquiring an additional 94 shares during the last quarter. Finally, Boston Financial Mangement LLC lifted its stake in shares of AbbVie by 4.4% during the 4th quarter. Boston Financial Mangement LLC now owns 32,997 shares of the company’s stock worth $5,864,000 after purchasing an additional 1,389 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Price Performance

Shares of NYSE ABBV opened at $200.98 on Friday. The company has a debt-to-equity ratio of 9.64, a current ratio of 0.65 and a quick ratio of 0.54. AbbVie Inc. has a 1-year low of $153.58 and a 1-year high of $207.32. The company has a market capitalization of $354.80 billion, a price-to-earnings ratio of 83.74, a PEG ratio of 1.56 and a beta of 0.58. The business has a 50-day moving average of $180.12 and a 200-day moving average of $186.19.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, January 31st. The company reported $2.16 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a return on equity of 257.91% and a net margin of 7.59%. During the same period last year, the business earned $2.79 EPS. On average, equities analysts anticipate that AbbVie Inc. will post 12.32 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be issued a dividend of $1.64 per share. This represents a $6.56 dividend on an annualized basis and a yield of 3.26%. The ex-dividend date is Tuesday, April 15th. AbbVie’s payout ratio is 273.33%.

Insider Buying and Selling

In related news, SVP Kevin K. Buckbee sold 1,800 shares of the business’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $172.24, for a total value of $310,032.00. Following the transaction, the senior vice president now owns 6,983 shares in the company, valued at approximately $1,202,751.92. The trade was a 20.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.25% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have recently commented on ABBV shares. Leerink Partners raised AbbVie from a “market perform” rating to an “outperform” rating and set a $206.00 price objective for the company in a research report on Friday, November 22nd. Leerink Partnrs upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a report on Friday, November 22nd. Morgan Stanley increased their price objective on shares of AbbVie from $224.00 to $239.00 and gave the stock an “overweight” rating in a report on Monday, February 3rd. Bank of America restated a “neutral” rating and issued a $191.00 target price on shares of AbbVie in a report on Tuesday, December 10th. Finally, Daiwa Capital Markets lowered shares of AbbVie from an “outperform” rating to a “neutral” rating and set a $180.00 price target for the company. in a research report on Thursday, December 5th. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $208.35.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.